Viking Therapeutics (VKTX) Assets (2014 - 2026)
Viking Therapeutics (VKTX) posted Assets of $521.9 million for Q2 2026, down 14.2% sequentially from $608.2 million in Q1 2026, and down 36.96% YoY from $827.9 million in Q2 2025.
Viking Therapeutics (VKTX) Assets (2014 - 2026) Analysis & Trends
Viking Therapeutics has reported Assets for 13 years, with the latest figure at $521.9 million in Q2 2026.
- Quarterly Assets fell 36.96% year-over-year to $521.9 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $521.9 million (down 36.96% YoY) and the FY2025 annual result came in at $715.7 million, down 21.2% from the prior year.
- Assets slipped to $521.9 million in Q2 2026 per VKTX's latest filing, from $608.2 million in the prior quarter.
- Over five years, Assets peaked at $967.5 million in Q1 2024 and troughed at $150.9 million in Q1 2023.
- A 5-year average of $558.6 million and a median of $565.1 million in 2026 frame the typical range for Assets.
- The sharpest annual moves came in 2024 and 2026: Assets surged 541.19% in 2024, then plunged 36.96% in 2026.
- Over 5 years, Assets stood at $168.5 million in 2022, then soared by 118.65% to $368.5 million in 2023, then surged by 146.5% to $908.3 million in 2024, then fell by 21.2% to $715.7 million in 2025, then declined by 27.08% to $521.9 million in 2026.
- According to Business Quant data, Assets over the past three periods registered $521.9 million, $608.2 million, and $715.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Viking Therapeutics | 3.87 Bn | 3.87 Bn | - | 521.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 521.90 Mn |
| Mar 31, 2026 | 608.24 Mn |
| Dec 31, 2025 | 715.73 Mn |
| Sep 30, 2025 | 739.42 Mn |
| Jun 30, 2025 | 827.85 Mn |
| Mar 31, 2025 | 866.99 Mn |
| Dec 31, 2024 | 908.32 Mn |
| Sep 30, 2024 | 937.89 Mn |
| Jun 30, 2024 | 946.84 Mn |
| Mar 31, 2024 | 967.52 Mn |
| Dec 31, 2023 | 368.49 Mn |
| Sep 30, 2023 | 382.66 Mn |
| Jun 30, 2023 | 400.69 Mn |
| Mar 31, 2023 | 150.90 Mn |
| Dec 31, 2022 | 168.53 Mn |
| Sep 30, 2022 | 166.68 Mn |
| Jun 30, 2022 | 181.51 Mn |
| Mar 31, 2022 | 195.03 Mn |
| Dec 31, 2021 | 210.66 Mn |
| Sep 30, 2021 | 224.47 Mn |